Atrial fibrillation patients do not benefit from acetylsalicylic acid
Conclusion
Acetylsalicylic acid as monotherapy in stroke prevention of atrial fibrillation has no discernable protective effect against stroke, and may even increase the risk of ischaemic stroke in elderly patients. Thus, our data support the new European guidelines recommendation that ASA as monotherapy should not be used as stroke prevention in atrial fibrillation.
Source: Europace - Category: Cardiology Authors: Sjalander, S., Sjalander, A., Svensson, P. J., Friberg, L. Tags: Atrial fibrillation Source Type: research
More News: Atrial Fibrillation | Bleeding | Cardiology | Hemorrhagic Stroke | Ischemic Stroke | Stroke | Study